A multi-center, randomized, double-blind, placebo- and positive-control, double-dummy, 3 parallel cohort, two-way crossover single oral dose study in GERD (gastro esophageal reflux disease) patients to evaluate the effects of AFQ056 and baclofen (positive control) on the incidence of meal-induced gastro esophageal reflux events

Trial Profile

A multi-center, randomized, double-blind, placebo- and positive-control, double-dummy, 3 parallel cohort, two-way crossover single oral dose study in GERD (gastro esophageal reflux disease) patients to evaluate the effects of AFQ056 and baclofen (positive control) on the incidence of meal-induced gastro esophageal reflux events

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Baclofen; Mavoglurant
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2007 Status change from recruiting to completed
    • 11 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top